CIPLA Share Price Performance
₹1,401.00
-69.20 (-4.71%)
2.0% undervalued intrinsic discount
₹1,429.83
Fair Value
Price ₹1,401.00
AnalystConsensusTarget ₹1,429.83
Fair Value₹1,429.83
Share Pricen/a
Analysis Article • May 16
Cipla Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 46 Fair Values set on narratives written by author
CIPLA Community Narratives
AN
Fair Value
·Fair Value ₹1.43k 2.0% undervalued intrinsic discount
Emerging Markets And Chronic Therapies Will Open New Horizons
0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
Emerging Markets And Chronic Therapies Will Open New Horizons
Key Takeaways Expansion in chronic therapies and complex generics, combined with digital and e-pharmacy investments, drives sustainable revenue and margin growth across key global markets. Manufacturing self-reliance and compliance strengths position Cipla to capitalize on supply chain shifts and localization trends, supporting long-term profitability and export growth.Read more
AN
₹1.43k
2.0% undervalued intrinsic discount
Fair Value
Revenue
9.02% p.a.
Profit Margin
15.04%
Future PE
30.17x
Price in 2029
₹2.03k
Trending Discussion
Recently Updated Narratives
AN
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Fair Value: ₹1.43k 2.0% undervalued intrinsic discount
26 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cipla Limited Key Details
About CIPLA
- Founded
- 1935
- Employees
- 30313
- CEO
- WebsiteView website
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
